Trials / Completed
CompletedNCT01736163
A Retrospective Observational Study Comparing Two Different Treatment Options in Thyroid Cancer Patients With T4 Tumours
A Retrospective, Non-interventional Study of Patients With T4 Tumours Comparing the Thyroid Remnant Ablation Success Following Thyrogen and 131I Administration Versus Thyroid Hormone Withdrawal and 131I Administration
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 144 (actual)
- Sponsor
- Genzyme, a Sanofi Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is to demonstrate non-inferior thyroid remnant first ablation success of Thyrogen and 131I compared to thyroid hormone withdrawal (THW) and 131I in patients with T4 tumour based on historical diagnostic whole body scan (DxWBS) records.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Thyrogen | 0.9 mg IM, administrated for 2 consecutive days |
| DRUG | 131I | 28 mCi or ≥ 1.036 GBq. |
| OTHER | Thyroid Hormone Withdrawal | Stop taking hormone therapy |
Timeline
- Start date
- 2012-05-01
- Primary completion
- 2012-08-01
- Completion
- 2012-08-01
- First posted
- 2012-11-29
- Last updated
- 2015-03-23
Locations
9 sites across 4 countries: Germany, Italy, Portugal, Spain
Source: ClinicalTrials.gov record NCT01736163. Inclusion in this directory is not an endorsement.